Time to Make a Change: Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine

Vincent A. Pallazola, Renato Quispe, Mohamed B. Elshazly, Rachit Vakil, Vasanth Sathiyakumar, Steven Jones, Seth Martin

Research output: Contribution to journalReview article

Abstract

Purpose of Review: The Friedewald equation for estimation of low-density lipoprotein cholesterol (LDL-C) was published in 1972 as an alternative to direct assessment by preparative ultracentrifugation. In this equation, very low-density lipoprotein is estimated by dividing triglycerides by a fixed factor (5 in mg/dL or 2.2 in mmol/L) and subtracting this term from non-high-density lipoprotein cholesterol (non-HDL-C). This method was derived in fasting samples from a small cohort of patients with primarily genetic dyslipidemias followed at the NIH. The method served well as the global standard for LDL-C estimation for decades, but is not well suited to modern clinical practice because it tends to underestimate LDL-C at low LDL-C and high triglyceride levels. The concern is that underestimation could lead to undertreatment in high-risk patients. Recent Findings: Derived from big data and now validated around the world, a novel LDL-C equation created at Johns Hopkins replaces the fixed factor seen in the classic equation with a patient-specific variable based on triglyceride and non-HDL-C levels. Summary: Given its superior accuracy in fasting and non-fasting populations alike, the novel equation is now the preferred method for LDL-C estimation and is being incorporated by leading clinical laboratories.

Original languageEnglish (US)
Article number26
JournalCurrent Cardiovascular Risk Reports
Volume12
Issue number11
DOIs
StatePublished - Nov 1 2018

    Fingerprint

Keywords

  • Cardiovascular prevention
  • Dyslipidemia
  • Friedewald equation
  • Lipid metabolism
  • Novel low-density lipoprotein equation
  • Precision medicine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this